James Davis
Amgen
9 Papers
136 Citations
James Davis is an academic researcher from Amgen. The author has contributed to research in topics: Calcimimetic & Hyperparathyroidism. The author has an hindex of 8, co-authored 9 publications.
Chat about Author
Papers
Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade.
Narender R. Gavva,Anthony W. Bannon,David N. Hovland,Sonya G. Lehto,Lana Klionsky,Sekhar Surapaneni,David C. Immke,Charles Henley,Leyla Arik,Annette Bak,James Davis,Nadia B. Ernst,Gal Hever,Rongzhen Kuang,Licheng Shi,Rami Tamir,Jue Wang,Weiya Wang,Gary Zajic,Dawn Zhu,Mark H. Norman,Jean-Claude Louis,Ella Magal,James J. S. Treanor +23 more
TL;DR: The in vitro and in vivo characterization of a novel and selective TRPV1 antagonist, AMG 517, and its pharmacology with that of a closely related analog, tert-butyl-2-(6-([2-(acetylamino)-1,3-benzothiazol-4-yl]oxy)pyrimidin- 4-yl)-5-(trifluoromethyl)phenylcarbamate (AMG8163) suggest that
182
The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats.
Charles Henley,James Davis,Gerald Miller,Edward Shatzen,Russ Cattley,Xiaodong Li,David Martin,Wei Yao,Nancy E Lane,Victoria Shalhoub +9 more
TL;DR: It is suggested that calcimimetics can reduce the development of vascular calcification, parathyroid hyperplasia and bone abnormalities associated with secondary hyperparathyroidism.
58
Cinacalcet HCl prevents development of parathyroid gland hyperplasia and reverses established parathyroid gland hyperplasia in a rodent model of CKD
TL;DR: The animal data provided suggest established parathyroid hyperplasia can be reversed by modulating CaSR activity with cinacalcet and that continued treatment may be necessary to maintain reductions in PTH.
42
Melanocortin subtype-4 receptor agonists containing a piperazine core with substituted aryl sulfonamides
Christopher H. Fotsch,Nianhe Han,Premilla Arasasingham,Yunxin Bo,Michelle Carmouche,Ning Chen,James Davis,Martin H. Goldberg,Clarence Hale,Feng-Yin Hsieh,Michael G. Kelly,Qingyian Liu,Mark H. Norman,Duncan M. Smith,Markian Stec,Nuria A. Tamayo,Ning Xi,Shimin Xu,Anthony W. Bannon,James W. Baumgartner +19 more
TL;DR: The biological activity for a set of melanocortin-4 receptor (MC4R) agonists containing a piperazine core with an ortho-substituted aryl sulfonamide is described, and the most selective compound in this series was >25,000-fold more potent at MC4R than MC3R, and 490-fold less potent than MC5R.
19
The discovery of an orally efficacious positive allosteric modulator of the calcium sensing receptor containing a dibenzylamine core.
Paul E. Harrington,David J. St. Jean,Jeffrey Clarine,Thomas Stephen Coulter,Michael Croghan,Adam Davenport,James Davis,Chiara Ghiron,Jonathan Hutchinson,Michael G. Kelly,Fred D. Lott,Jenny Ying-Lin Lu,David Martin,Sean Morony,Steve F. Poon,Elena Portero-Larragueta,Jeff D. Reagan,Kelly Regal,Andrew Tasker,Minghan Wang,Yuhua Yang,Guomin Yao,Qingping Zeng,Charles Henley,Christopher H. Fotsch +24 more
TL;DR: A series of novel and orally efficacious type II calcimimetics, developed from the lead compound 1, are discovered and suppressed plasma PTH levels relative to vehicle when dosed orally in a rat pharmacodynamic model.
13